MedKoo Cat#: 563507 | Name: SR13800
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

SR13800 is a cell-permeable inhibitor of monocarboxylate transporter 1 (MCT1).

Chemical Structure

SR13800
CAS#227321-12-2

Theoretical Analysis

MedKoo Cat#: 563507

Name: SR13800

CAS#: 227321-12-2

Chemical Formula: C25H29N3O2S

Exact Mass: 435.1980

Molecular Weight: 435.58

Elemental Analysis: C, 68.94; H, 6.71; N, 9.65; O, 7.35; S, 7.36

Price and Availability

Size Price Availability Quantity
10mg USD 600.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
SR13800; SR-13800; SR 13800;
IUPAC/Chemical Name
7-((3-hydroxypropyl)thio)-4-isobutyl-2-methyl-6-(naphthalen-1-ylmethyl)-2,6-dihydro-1H-pyrrolo[3,4-d]pyridazin-1-one
InChi Key
VDAVMXLEMHVXOG-UHFFFAOYSA-N
InChi Code
InChI=1S/C25H29N3O2S/c1-17(2)14-22-21-16-28(15-19-10-6-9-18-8-4-5-11-20(18)19)25(31-13-7-12-29)23(21)24(30)27(3)26-22/h4-6,8-11,16-17,29H,7,12-15H2,1-3H3
SMILES Code
O=C1C2=C(SCCCO)N(CC3=C4C=CC=CC4=CC=C3)C=C2C(CC(C)C)=NN1C
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 435.58 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Kim J, Park S, Kim S, Ryu S, Hwang H, Cho S, Han Y, Kim J, Park Y, Lee EK, Lee M. Enhancing the anticancer effect of androgen deprivation therapy by monocarboxylate transporter 1 inhibitor in prostate cancer cells. Prostate. 2024 Jun;84(9):814-822. doi: 10.1002/pros.24700. Epub 2024 Apr 1. PMID: 38558458. 2: Chatterjee P, Bhowmik D, Roy SS. A systemic analysis of monocarboxylate transporters in ovarian cancer and possible therapeutic interventions. Channels (Austin). 2023 Dec;17(1):2273008. doi: 10.1080/19336950.2023.2273008. Epub 2023 Nov 7. PMID: 37934721; PMCID: PMC10631444. 3: Padilla J, Lee BS, Zhai K, Rentz B, Bobo T, Dowling NM, Lee J. A Heme-Binding Transcription Factor BACH1 Regulates Lactate Catabolism Suggesting a Combined Therapy for Triple-Negative Breast Cancer. Cells. 2022 Mar 31;11(7):1177. doi: 10.3390/cells11071177. PMID: 35406740; PMCID: PMC8997507. 4: Khan A, Valli E, Lam H, Scott DA, Murray J, Hanssen KM, Eden G, Gamble LD, Pandher R, Flemming CL, Allan S, Osterman AL, Haber M, Norris MD, Fletcher JI, Yu DMT. Targeting metabolic activity in high-risk neuroblastoma through Monocarboxylate Transporter 1 (MCT1) inhibition. Oncogene. 2020 Apr;39(17):3555-3570. doi: 10.1038/s41388-020-1235-2. Epub 2020 Mar 2. PMID: 32123312; PMCID: PMC7970707. 5: Murray CM, Hutchinson R, Bantick JR, Belfield GP, Benjamin AD, Brazma D, Bundick RV, Cook ID, Craggs RI, Edwards S, Evans LR, Harrison R, Holness E, Jackson AP, Jackson CG, Kingston LP, Perry MW, Ross AR, Rugman PA, Sidhu SS, Sullivan M, Taylor-Fishwick DA, Walker PC, Whitehead YM, Wilkinson DJ, Wright A, Donald DK. Monocarboxylate transporter MCT1 is a target for immunosuppression. Nat Chem Biol. 2005 Dec;1(7):371-6. PubMed PMID: 16370372.